21st Century Cures Act

21st Century Cures Act
U.S. Government · Public domain · source
Title	21st Century Cures Act
Enacted by	114th United States Congress
Enacted	December 13
Year	2016
Public law	Public Law 114–255
Introduced by	Fred Upton (R–Michigan) and Diana DeGette (D–Colorado)
Committees	House Energy and Commerce Committee, Senate Health, Education, Labor and Pensions Committee
Signed by	Barack Obama

21st Century Cures Act The 21st Century Cures Act was a United States federal law enacted in 2016 to accelerate medical product development, support biomedical research, reform Food and Drug Administration processes, and expand mental health and opioid treatment initiatives. It combined provisions championed by legislators, industry groups, patient advocates, and research institutions, aiming to streamline regulatory pathways while increasing funding for programs administered by agencies such as the National Institutes of Health and the Substance Abuse and Mental Health Services Administration. The Act influenced policy debates involving stakeholders including pharmaceutical companies, academic centers like Johns Hopkins University, patient organizations such as the Alzheimer's Association, and state authorities like the California Department of Public Health.

Background and Legislative History

The Act emerged from bipartisan efforts by lawmakers including Fred Upton, Diana DeGette, Lamar Alexander, and Patty Murray and reflected advocacy from groups such as the Pharmaceutical Research and Manufacturers of America, Biotechnology Innovation Organization, and the Mayo Clinic. Legislative movement built on prior statutes and reports from entities like the Institute of Medicine and the National Academies of Sciences, Engineering, and Medicine, and paralleled initiatives such as the American Recovery and Reinvestment Act of 2009's research funding. Key hearings occurred before committees including the House Energy and Commerce Committee and the Senate HELP Committee, with testimony from officials at the Food and Drug Administration, National Institutes of Health, and patient advocates from organizations including Susan G. Komen and Autism Speaks. Political negotiation involved executive-branch actors such as Barack Obama and lobbying by corporations like Pfizer, Amgen, Gilead Sciences, and academic consortia including Association of American Medical Colleges.

Major Provisions and Programs

Provisions funded and reauthorized programs at agencies including the National Institutes of Health, Food and Drug Administration, Substance Abuse and Mental Health Services Administration, and the Office of the National Coordinator for Health Information Technology. The Act created or expanded initiatives such as increased funding for the Precision Medicine Initiative, support for the BRAIN Initiative, grants to institutions like Harvard University and Stanford University for translational research, and incentives for orphan drug development involving stakeholders like Genentech and Biogen. It included measures affecting electronic health records interoperability overseen by ONC and engaged vendors such as Epic Systems and Cerner Corporation. Mental health and opioid components allocated resources to programs run by SAMHSA and state partners such as the New York State Department of Health and Ohio Department of Mental Health and Addiction Services, while research funding supported cooperative research networks including the Clinical and Translational Science Awards program and partnerships with institutions like National Cancer Institute and Centers for Disease Control and Prevention.

Funding and Appropriations

The law authorized and appropriated funds to the National Institutes of Health, including targeted support for organizations like the National Institute of Mental Health and the National Institute on Drug Abuse, with grants managed through award mechanisms involving National Institutes of Health Office of Extramural Research. It financed opioid response programs administered by Substance Abuse and Mental Health Services Administration and distributed through state agencies such as the Massachusetts Department of Public Health and Kentucky Cabinet for Health and Family Services. Appropriations interacted with budget processes in the Congressional Budget Office and Office of Management and Budget, and affected funding flows to public hospitals like Johns Hopkins Hospital and research centers including the Fred Hutchinson Cancer Center. Private supporters included philanthropy from entities such as the Bill & Melinda Gates Foundation and collaborations with biopharmaceutical firms like Novartis for clinical trial networks.

Regulatory and Policy Changes

The Act directed regulatory reforms within the Food and Drug Administration, modifying evidentiary standards and guidance for clinical trial endpoints, real-world evidence, and surrogate markers, engaging stakeholders including FDA Commissioner offices, academic centers like Duke University School of Medicine, and industry groups such as PhRMA. It advanced policies on electronic health record interoperability and information blocking, involving Office of the National Coordinator for Health Information Technology and standards bodies like Health Level Seven International and the Clinical Data Interchange Standards Consortium. The statute affected data privacy and sharing debates relevant to Health Insurance Portability and Accountability Act implementation, engaging privacy advocates and institutions including the American Civil Liberties Union and the Electronic Frontier Foundation. Changes influenced approval pathways used by manufacturers including Johnson & Johnson and Roche and enrollment practices overseen by institutional review boards at universities like Yale School of Medicine.

Implementation, Impact, and Criticism

Implementation involved federal agencies NIH, FDA, SAMHSA, and state health departments such as California Department of Public Health and Florida Department of Health, with program execution by research institutions including University of California, San Francisco and University of Pittsburgh Medical Center. Supporters including AdvaMed and patient groups such as Alzheimer's Association praised accelerated development and increased research funding. Critics—ranging from Public Citizen and Union of Concerned Scientists to journalists at The New York Times and ProPublica—raised concerns about lowered evidentiary standards, potential influence by pharmaceutical firms like Merck and Eli Lilly and Company, and privacy implications highlighted by groups such as Electronic Frontier Foundation. Empirical assessments by think tanks including the Brookings Institution and the Kaiser Family Foundation examined impacts on drug approval timelines, clinical trial design, and opioid treatment capacity, while litigation and oversight studies by the Government Accountability Office and Congressional committees scrutinized implementation outcomes. Overall, the Act reshaped research funding trajectories and regulatory practices, provoking ongoing debate among stakeholders such as patients, clinicians, researchers, and policy organizations including Health Affairs and The Commonwealth Fund.

Category:United States federal health legislation